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Abstract
Background: Due to the alarming increase in the incidence of thyroid cancer worldwide, more patients are receiving
postoperative radioactive iodine (RAI) therapy and these patients are given a low-iodine diet along with levothyroxine
withdrawal to induce a hypothyroid state to maximize the uptake of RAI by thyroid tissues. Recently, the reported cases of
patients suffering from life-threatening severe hyponatremia following postoperative RAI therapy have increased. This study
aimed to systematically assess risk factors for developing hyponatremia following RAI therapy in post-thyroidectomy
patients.
Methods: We reviewed the medical records of all thyroid cancer patients who underwent thyroidectomy and postoperative
RAI therapy from July 2009 to February 2012. Demographic and biochemical parameters including serum sodium and
thyroid function tests were assessed along with medication history.
Results: A total of 2229 patients (47.0611.0 years, female 76.3%) were enrolled in the analysis. Three hundred seven patients
(13.8%) of all patients developed hyponatremia; 44 patients (2.0%) developedmoderate to severe hyponatremia (serum Na+#
130 mEq/L) and another 263 (11.8%) patients showed mild hyponatremia (130 mEq/L,serum Na+#135 mEq/L). In univariate
analysis, old age, female sex, presence of hypertension, presence of diabetes, use of thiazide diuretics, use of angiotensin
receptor blocker or angiotensin-converting enzyme inhibitors, lung metastasis, and hyponatremia and lower estimated
glomerular filtration rate at the start of RAI therapy were significantly associated with hyponatremia in patients undergoing
RAI therapy after total thyroidectomy. Multivariate analysis showed that old age, female sex, use of thiazide diuretics, and
hyponatremia at the initiation of RAI therapy were independent risk factors for the development of hyponatremia.
Conclusion: Our data suggest that age greater than 60 years, female sex, use of thiazide, and hyponatremia at the initiation
of RAI therapy are important risk factors for developing hyponatremia following RAI therapy in post-thyroidectomy patients.
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Introduction
In the last decades, the incidence of thyroid cancer has
increased at an alarming rate worldwide [1]. Differentiated
thyroid cancer (DTC) accounts for the vast majority of thyroid
cancers and initial treatment includes ablative radioactive iodine
(RAI) therapy after thyroidectomy [2]. Long-term comprehensive
studies have demonstrated that ablative RAI therapy decreases the
rates of regional recurrences and disease-associated mortality [3].
Many centers use treatment protocols that include thyroid
hormone withdrawal and 2–4 weeks of a low-iodine diet prior to
RAI therapy to minimize dietary iodine interference and induce
hypothyroid status for facilitating the uptake of RAI [3]. Iatrogenic
hypothyroid status induced by such treatment protocol may
impair water excretion and cause mild hyponatremia. Such a low-
iodine diet protocol is frequently accompanied by low dietary salt
intake. In addition, these patients are encouraged to increase oral
fluid intake during RAI therapy to flush out the iodine. Thus, the
disturbances in the serum sodium concentration may be further
aggravated by low dietary salt and increased oral fluid intake
during RAI therapy.
Until now, few studies have investigated the incidence and
severity of hyponatremia in hypothyroid patients following RAI
therapy after thyroidectomy. A previous retrospective analysis of
patients who underwent thyroid-ablation in the setting of thyroid
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hormone withdrawal performed by Baajafer el al. demonstrated
that only few acute hypothyroid patients experienced hyponatre-
mia and none of the patients had severe symptomatic hyponatre-
mia [4]. The same authors also reported in a prospective study of
212 thyroid cancer patients undergoing RAI therapy that
clinically-important hyponatremia was uncommon [5]. However,
there have been a few case reports of severe symptomatic
hyponatremia in acute hypothyroid patients undergoing RAI
therapy [6–8]. We also recently experienced life-threatening
severe hyponatremia in two patients at our center [9].
Thus, the aim of this study was to systematically evaluate the
incidence and risk factors for development of hyponatremia after
RAI therapy in thyroid cancer patients who underwent total
thyroidectomy.
Materials and Methods
Study population
Data for a total of 2241 DTC patients who consecutively
underwent bilateral total thyroidectomy with central compartment
neck dissection and RAI therapy at Gangnam Severance hospital
were collected from July 2009 to February 2012. We excluded 12
patients due to absence of the complete set of laboratory findings
for serum sodium, free T4 (fT4), or thyroid stimulating hormone
(TSH). Thus, the data for 2229 patients were analyzed. All of the
patients were treated using the same RAI therapy protocol of our
thyroid cancer center. Briefly, after thyroidectomy, the patients
took levothyroxine daily for four weeks and then they were
switched to liothyronine daily for another two weeks. After that,
the patients were advised to follow a low iodine diet along with
thyroid hormone withdrawal for two weeks prior to RAI therapy.
This study was approved by the Ethics Committee of the
Gangnam Severance Hospital (#3-2014-0039). A written in-
formed consent was not necessary because this was a retrospective
cohort study.
Laboratory data
Baseline blood tests, including renal function screening and
serum electrolyte testing, were performed on the day of admission
for RAI therapy. Serum sodium concentrations were obtained at
baseline and at the time when the patients were cleared for
discharge or upon the development of clinical symptoms. The
following demographic data were collected; age, sex, use of anti-
hypertensive medications such as thiazide or angiotensin receptor
blocker (ARB) or angiotensin-converting enzyme inhibitors
(ACEi), presence of co-morbidities such as diabetes or hyperten-
sion, and presence of lung or brain metastasis. After we identified
baseline characteristics of all the patients, we divided them into
three groups according to the serum sodium level as follows: (1) the
moderate to severe hyponatremia group, in which the lowest
serum sodium level within seven days after RAI therapy was less
than 130 mEq/L (n= 44, 2.0%), (2) the mild hyponatremia group,
in which the serum sodium level was 131,135 mEq/L (n= 263,
11.8%), and (3) the normonatremic group, in which the lowest
serum sodium level within seven days after RAI therapy was more
than 136 mEq/L (n = 1922, 86.2%). Serum sodium and creatinine
concentrations were determined using an Olympus AU 2700
analyzer. The normal range of serum sodium is 136–146 mEq/L.
Serum TSH and free thyroxine concentrations were determined
using the Abbott TSH assay, free thyroxine assay kits, and an
Abbott Architect i1000 analyzer. The normal ranges for fT4 and
TSH are 0.7–1.48 ng/dL and 0.35–4.94 mcIU/mL, respectively.
The estimated glomerular filtration rate (eGFR) was calculated
using the simplified Modification of Diet in Renal Disease formula
(MDRD) and chronic renal failure was defined as an eGFR less
than 60 ml/min/1.73 m2. Also, the decrease rate in the eGFR
during RAI therapy was calculated using the following formula:
eGFR decrease rate = (pre-RAI therapy eGFR2post-RAI therapy
eGFR)4pre-RAI therapy eGFR.
Statistical analysis
Continuous variables are presented as mean 6 SD, and
categorical variables as numbers and percentages. Baseline
characteristics of the patients were compared using the student’s
t test for continuous variables and x2 test for categorical variables.
We performed univariate and multivariate logistic regression
analyses to determine the association between clinical variables
and hyponatremia following RAI therapy in patients with thyroid
cancer. Prior to conducting logistic regression analysis to
determine the influence of each variable on susceptibility to
developing hyponatremia after RAI therapy, we confirmed that
the proportion of patients diagnosed with hypertension increased
with age when estimated by linear association and all of the
thiazide medication users had hypertension. Therefore, hyperten-
sion was excluded from the variables because multicollinearity
could occur between hypertension, old age (greater than 60 years),
and thiazide medication use in the logistic regression analysis.
P-values less than 0.05 were considered to be statistically
significant. All statistical analyses were performed using SAS
version 9.2 (SAS Institute Inc. Cary, NC, USA).
Results
Study population
A total of 2,229 patients (76.3% females, mean age 47.0611.0
years) were included in this study. Among them, 97% of patients
had papillary thyroid cancer. In the total 2,229 patients, 15.8% of
patients were more than 60 years of age, and 13.8% of patients
had hyponatremia. Among them, 8 (0.35%) patients showed
severe hyponatremia and the serum sodium level was less than
120 mEq/L following RAI therapy. Thirty patients (1.3%) had
underlying chronic renal failure, which was defined as eGFR less
than 60 ml/min/1.73 m2. Fifteen percent of the patients had
hypertension, and six percent of patients had diabetes. Four
percent of all patients used thiazide diuretics, and nine percent of
all patients took ARB or ACEi. Twenty-three patients (1.0%) had
lung metastasis, but none of the patients had brain metastasis.
When parameters were compared between the normonatremia,
mild hyponatremia, and moderate to severe hyponatremia groups,
statistically significant differences were found in age, sex, presence
of hypertension or diabetes, use of thiazide or ARB medications,
lung metastasis, serum sodium, calcium, and albumin. These
results are summarized in Table 1. Compared with the patients in
the normonatremia group, patients with varying degrees of
hyponatremia were older and suffered from hypertension or
diabetes more frequently, had lung metastasis more frequently, or
had used thiazide or ARB more frequently. There were greater
number of females among all of the hyponatremic patients
belonging to the moderate to severe hyponatremia and mild
hyponatremia groups than in the normonatremia group (81.7% vs.
75.4%, p= 0.016). The mean serum sodium and eGFR at the start
of RAI therapy in the patients of the moderate to severe
hyponatremia and mild hyponatremia groups were lower than
those in the patients of the normonatremia group. Serum fT4, T3,
and TSH levels were not significantly different among three
groups. The decrease rate in the eGFR following RAI therapy was
not significantly different among three groups according to serum
sodium levels (p = 0.184) (Fig. 1).
Risk Factors of Hyponatremia following Radioactive Iodine Therapy
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Figure 1. Comparison of eGFR decrease rate between pre- and post- RAI therapy.
doi:10.1371/journal.pone.0106840.g001
Table 1. Baseline characteristics of patients and changes in various laboratory findings according to the sodium status following
RAI therapy.
Moderate to severe Hyponatremia
(n =44)
Mild hyponatremia
(n =263)
Normo-natremia
(n =1922) P value
Age (years) 61.9611.2 49.1613.8 46.5611.3 ,0.0001
Age $60 years, n (%) 27(61.3) 65(24.7) 262(13.6) ,0.0001
Female sex, n (%) 32(72.7) 219(83.2) 1449(75.4) 0.016
Hypertension, n (%) 24(54.5) 59(22.4) 255(13.2) ,0.0001
DM, n (%) 5(11.3) 30(11.4) 103(5.3) 0.002
Thiazide use, n (%) 11(25.0) 24(9.1) 67(3.5) ,0.0001
ARB or ACEi use, n (%) 10(22.7) 41(15.5) 157(8.2) 0.002
Lung metastasis, n (%) 3(6.8) 4(1.5) 16(0.8) 0.005
Laboratory findings before RAI
therapy
fT4 0.1460.09 0.1260.05 0.1260.07 0.245
T3 (ng/dL) 24.9610.3 23.167.7 23.368.9 0.453
TSH (mcIU/mL) 79.7621.8 81.3620.9 79.2620.4 0.300
Na (mEq/L) 137.163.6 138.862.0 139.961.8 0.000
Cr (mg/dL) 0.9760.37 0.9060.25 0.8960.23 0.111
eGFR (ml/min/1.73 m2) 75.05623.01 81.26622.74 83.40622.02 0.019
Ca (mg/dL) 9.1760.72 9.2160.63 9.1060.63 0.027
Albumin (g/dL) 4.4360.44 4.5060.28 4.5460.27 0.003
Note: values for categorical variables are expressed as number (percentage); values for continuous variables are expressed as mean 6 standard deviation.
Abbreviations: DM, diabetes mellitus; ARB, angiotensin receptor blocker; ACEi, angiotensin converting enzyme inhibitor; RAI, radioactive iodine; TSH, thyroid stimulating
hormone; eGFR, estimated glomerular filtration rate.
doi:10.1371/journal.pone.0106840.t001
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In-depth findings in moderate to severe hyponatremic
patients
The medical records of moderate to severe hyponatremic
patients (n = 44, females 32) were reviewed in detail to investigate
the clinical characteristics and possible risk factors for developing
clinically significant hyponatremia after RAI therapy. Among
these 44 patients, 11 patients had used thiazide diuretics, 10
patients had used ARB or ACEi, and 3 patients had lung
metastasis. The serum creatinine level in one female patient was
2.9 mg/dL and the serum creatinine levels in the remaining
patients were less than 1.5 mg/dL when they started RAI therapy.
At that time, fourteen patients already had decreased renal
function, which was defined as an eGFR less than 60 ml/min/m2.
All of the 44 patients had nausea or vomiting following RAI
therapy and needed to visit the outpatient clinic or the emergency
room. Eight of these 44 patients showed severe hyponatremia,
which was defined as serum sodium level less than 120 mEq/L
(mean 116 mEq/L, range 108,119 mEq/L). All of these eight
patients were females and they were more than 60 years of age,
excluding one female patient, who was 47 years old. Six of these
patients had hypertension; 3 patients took ARB or ACEi, and 3
patients took thiazide medication. The type of thyroid cancer was
papillary cancer in all patients, excluding one patient, who had
follicular carcinoma. None of the patients had metastasis to the
other sites. All of the patients who had nausea or vomiting visited
the emergency room within an average 2.3 days (range, 1,4 days)
following RAI therapy. The plasma osmolarity of all patients with
available data were decreased indicating presence of true
hyponatremia. Most of urine osmolarity values were greater than
100 mosm/kg that indicates an impairment of free water
excretion. The urine sodium level of these patients were rather
low suggesting possible dehydration due to nausea and vomiting
(Table 2).
The determinants of hyponatremia following RAI therapy
in thyroid cancer patients
We performed univariate and multivariate logistic regression
analyses to evaluate the determinants of hyponatremia following
RAI therapy in thyroid cancer patients. In univariate analysis, old
age, above 60 years, female sex, presence of hypertension,
presence of diabetes, thiazide use, use of ARB or ACE inhibitors,
lung metastasis, and hyponatremia at the start of RAI were
significantly associated with hyponatremia in patients who
underwent RAI therapy after total thyroidectomy. Also, lower
eGFR, higher calcium, and lower albumin levels in the serum
were significantly associated with hyponatremia in thyroid cancer
patients following RAI therapy (Table 3). However, in the
multivariate analysis, old age, female sex, presence of DM,
thiazide use, and hyponatremia at the start of RAI therapy were
independently associated with the development of hyponatremia
following RAI therapy in thyroid cancer (Table 4).
Discussion
The primary findings of this study are that old age (especially
above 60 years), female sex, thiazide use, and pre-RAI treatment
hyponatremia are independent risk factors for developing hypo-
natremia following RAI therapy in thyroid cancer patients with
total thyroidectomy.
These findings were partly consistent with those of previous case
reports [8,9]. In one case report, a 66 year old female patient
visited the emergency room and had serum sodium level of
107 mEq/L after low-iodine diet for thyroid ablation, and the
author suggested that prolonged low-iodine diet, low salt intake,
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and use of thiazide diuretics in elderly patients were risk factors for
the development of life-threatening hyponatremia [8]. As can be
seen in previous case reports [6–10], most of the patients were
above 60 years of age and all of the patients showed quite severe
hyponatremia with serum sodium levels ranging from 107 mEq/L
to 121 mEq/L. In contrast to the earlier case reports [6–10], in a
recent prospective study of 212 patients with DTC [5], 8.5% of
the patients had mild hyponatremia (serum sodium level,
130–136 mEq/L) and 1.9% of the patients had moderate to
severe hyponatremia (serum sodium level less than 130 mEq/L),
and none of the patients had a serum sodium level less than
120 mEq/L. Hence, the authors asserted that clinically-important
hyponatremia was uncommon and sodium concentration might
not need to be monitored unless the patients had impaired renal
function or they were on diuretics in the setting of acute severe
hypothyroidism. Our current study also showed that 11.8% of
Table 3. Univariate logistic regression analysis showing the association between various parameters and hyponatremia
(vs. normonatremia).
Odds ratio 95% CI P-value
Overall
p-value
Age .60 years (vs. ,59 years)
Moderate to severe 10.063 5.410–18.719 ,0.0001 ,0.0001
Mild 2.08 1.527–2.833 ,0.0001
Sex (male vs. female)
Moderate to severe 1.149 0.587–2.248 0.6856 0.0173
Mild 0.615 0.438–0.865 0.0051
HTN (vs. No HTN)
Moderate to severe 7.845 4.272–14.407 ,0.0001 ,0.0001
Mild 1.891 1.375–2.599 ,0.0001
DM (vs. no DM)
Moderate to severe 2.264 0.874–5.866 0.0925 0.0044
Mild 2.274 1.481–3.492 0.0002
Thiazide (vs. no use)
Moderate to severe 9.236 4.476–19.060 ,0.0001 ,0.0001
Mild 2.780 1.711–4.517 ,0.0001
ARB or ACEi (vs. no use)
Moderate to severe 3.330 1.614–6.867 0.0011 ,0.0001
Mild 2.091 1.442–3.030 ,0.0001
Lung metastasis (vs. no mets)
Moderate to severe 8.716 2.444–31.082 0.0008 0.0033
Mild 1.842 0.611–5.550 0.2780
Na level on RAI
Moderate to severe 0.557 0.486–0.637 ,0.0001 ,0.0001
Mild 0.74 0.688–0.795 ,0.0001
TSH level on RAI
Moderate to severe 1.001 0.987–1.016 0.8742 0.3000
Mild 1.005 0.999–1.012 0.1220
eGFR on RAI
Moderate to severe 0.979 0.963–0.996 0.0134 0.0186
Mild 0.995 0.989–1.002 0.1424
eGFR decrease rate
Moderate to severe 0.996 0.981–1.012 0.6251 0.1621
Mild 1.007 0.999–1.015 0.0740
Ca on RAI
Moderate to severe 1.203 0.743–1.946 0.4525 0.0272
Mild 1.323 1.072–1.632 0.0090
Albumin on RAI
Moderate to severe 0.273 0.100–0.745 0.0112 0.0034
Mild 0.575 0.364–0.906 0.0172
Abbreviations: HTN, hypertension; DM, diabetes mellitus; ARB, angiotensin receptor blocker; ACEi angiotensin converting enzyme inhibitor; mets, metastasis.
doi:10.1371/journal.pone.0106840.t003
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patients had mild hyponatremia (serum sodium level,
131,137 mEq/L) and only 2.0% of the patients had moderate
to severe hyponatremia (serum sodium level less than 130 mEq/
L), respectively. These findings support the observation that severe
life-threatening hyponatremia did not occur more commonly than
expected. However, the finding of 2.0% of patients having
moderate to severe hyponatremia should not be considered trivial
as the number of thyroid cancer patients are increasing at an
alarming rate worldwide and more patients are undergoing RAI
treatment. Furthermore, it should not be ignored because all of the
44 patients with moderate to severe hyponatremia in our study
showed severe general weakness, nausea or vomiting that
necessitated visit to the outpatient clinic or emergency room.
Also, in our study, the median age of patients was 47 years, and
76.3% of patients were females. The mean age of the thyroid
cancer patients is 46.8 years in Korea [11] and the reported
median age at diagnosis of thyroid cancer in the United States of
America is 46 years with female predominance [1]. As our data
might be representative of the general population of thyroid
cancer patients in Korea or United States, our data demonstrated
high reliability of the results and solidified risk factors for the
development of hyponatremia following RAI therapy in thyroid
cancer patients through multivariate analysis in a large number of
patients.
In clinical practice, dilutional hyponatremia is a common
feature of severe hypothyroidism. The possible mechanisms for the
development of hyponatremia in a hypothyroid condition is the
inability to excrete a free water load caused by both a decrease in
the delivery of water to the distal nephron [12] and excess
antidiuretic hormone (ADH) secretion [13]. The glomerular
filtration rate is also decreased in hypothyroidism. This can
directly diminish free water excretion by diminishing water
delivery to the diluting segments [14]. With normal or increased
fluid intake, hyponatremia generally results from the inability to
decrease urine osmolality below the plasma level failure to
suppress maximally the ADH secretion [15]. Due to this
mechanism, hypothyroidism may be proposed to be a major risk
factor of developing hyponatremia. However, our data showed
that hypothyroidism due to thyroid hormone withdrawal was not
significantly correlated with post RAI hyponatremia. This finding
seems to be consistent with that in another study, which showed
that hyponatremia is not necessarily a consequence of hypothy-
roidism [16]. Taken together, no causal association between
hypothyroidism and hyponatremia has been definitively demon-
strated. Our current findings suggest there are other risk factors
that are associated with development of hyponatremia in post-RAI
therapy.
In our study, old age was one of risk factors of hyponatremia
following RAI therapy. There is a delay in the ability of the senile
Table 4. Significant predictors ofdeveloping hyponatremia after RAI therapy by multiple logistic regression analysis
(vs. normonatremia).
Odds ratio 95% CI P-value
Overall
p-value
Age .60 years (vs. ,59 years)
Moderate to Severe 8.817 4.296–18.095 ,0.0001 ,0.0001
Mild 1.875 1.321–2.662 0.0004
Sex (male vs female)
Moderate to Severe 0.979 0.456–2.103 0.9575 0.0082
Mild 0.570 0.398–0.814 0.0020
DM (vs. DM)
Moderate to Severe 0.732 0.227–2.361 0.6017 0.0653
Mild 1.710 1.048–2.791 0.0318
Thiazide (vs. no use)
Moderate to Severe 5.139 1.880–14.045 0.0014 0.0027
Mild 1.900 1.024–3.526 0.0419
ARB (vs. no use)
Moderate to Severe 1.597 0.576–4.430 0.3684 0.4277
Mild 0.824 0.500–1.358 0.4476
Lung metastasis (vs. no mets)
Moderate to Severe 1.552 0.282–8.548 0.6134 0.8727
Mild 1.052 0.287–3.854 0.9393
Na on RAI therapy
Moderate to Severe 0.566 0.488–0.657 ,0.0001 ,0.0001
Mild 0.726 0.674–0.783 ,0.0001
eGFR on RAI therapy
Moderate to Severe 0.989 0.974–1.005 0.1715 0.0535
Mild 0.993 0.987–0.999 0.0520
Abbreviations: DM, diabetes mellitus; ARB, angiotensin receptor blocker; ACEi, angiotensin converting enzyme inhibitor; mets, metastasis; RAI, radioactive iodine; eGFR,
estimated glomerular filtration rate.
doi:10.1371/journal.pone.0106840.t004
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kidney to lower sodium excretion in a hyponatremic state [17].
Compared to younger individuals, elderly patients in a hypothy-
roid state are more susceptible to hyponatremia because of
excessive ADH [18,19]. Therefore, we assumed that elderly
patients in a hypothyroid state are at higher risk for hyponatremia
compared with younger individuals due to excessive ADH. In
addition, use of thiazide diuretics was an independent risk factor
for hyponatremia post RAI therapy in our study. The efficacy of
ADH depends on the generation of the medullary concentration
gradient via NaCl reabsorption in the absence of water, in the
thick ascending limb of the loop of Henle. This creates a gradient
for water reabsorption via aquaporin-2 insertion in the luminal
membranes of the cortical and outer medullary collecting tubules.
When hypothyroid patients fail to suppress plasma ADH [13,20],
thiazide acts on the distal tubule, which is not influenced by the
medullary concentration gradient, thereby allowing ADH to
promote water reabsorption unabated in comparison to loop
diuretics [21–24]. This may be the reason why thiazide use was
associated with hyponatremia following RAI therapy in our study.
Also, ARB has a modest natriuretic effect that could induce
hyponatremia [25]. In a cross-sectional study of elderly hypona-
tremic patients presenting to the emergency room, 43.8% of
patients were using blockers of the renin-angiotensin system such
as ARB or ACEi, some with no associated thiazide diuretic [26].
The risk of hyponatremia should not be underestimated in patients
taking ARB. In our study, the use of ARB or ACEi was associated
with hyponatremia after RAI therapy on univariate analysis, but
when we performed multivariate analysis, the use of ARB or ACE
inhibitors lost its statistical validity. Thus, the effect of ARB or
ACEi on hyponatremia can be considered insignificant.
Some authorities have indicated that although a low-iodine diet
does not mean a low-sodium diet, many patients eat a low-iodine
diet with low-sodium diet in spite of the availability of iodine-free
salt [6]. Therefore, hyponatremia can be aggravated during a low-
iodine diet period. Likewise, in our study, the mean serum sodium
level immediately before RAI therapy following prolonged
levothyroxine withdrawal was lower than the mean serum sodium
level immediately after thyroidectomy (data not shown;
139.761.9 mEq/L vs. 140.062.1 mEq/L, p= 0.015). Although
not stated in the results, severe hyponatremia did not occur
immediately before RAI therapy (the lowest serum sodium level at
the start of RAI therapy was 126 mEq/L). We observed that the
occurrence of severe hyponatremia was less common than we
expected before RAI therapy. Thus, this finding suggested that
severe hyponatremia occurred more frequently after RAI therapy.
In other case reports [6,10], because most patients had
metastasis to other sites, the authors hypothesized that metastasis
might be associated with the development of hyponatremia. Head
and neck cancers are responsible for only 1.5% of syndrome of
inappropriate secretion of ADH (SIADH) [24] and a rare case
report suggested that SIADH can be related to thyroid cancer
[27]. In our univariate analysis, we found that lung metastasis had
significant association with hyponatremia in moderate to severe
group. However, the relationship between lung metastasis and
hyponatremia lost its statistical significance on multivariate
analysis. Based on our results, lung metastasis is not an
independent risk factor for developing hyponatremia following
RAI therapy. Therefore, it is difficult to conclude that SIADH due
to lung metastasis contributed to the occurrence of hyponatremia
in thyroid cancer patients.
Hypothyroidism is also widely accepted as a cause of
hypercreatininemia [28]. Baajafer et al. [28] reported that mild
elevation in serum creatinine level was common in patients with
hypothyroidism. Hammami et al. [5] also showed that hypona-
tremic patients were more likely to have elevated creatinine
concentration. However, our findings suggested that there were no
differences on eGFR decrease rate according to the sodium status
following RAI therapy. In addition, we did not find a significant
association between renal dysfunction at the start of RAI therapy
and the occurrence of hyponatremia during RAI therapy on
multivariate analysis. These discrepancies cannot be easily
explained, but they are attributable to different characteristics
and sizes of the study populations.
There are some limitations to our study. First, because the
current study was retrospective in nature, we cannot rule out the
possibility of residual confounding due to variable selection bias.
However, the present study is the largest study to date and it
enrolled patients who had similar age or gender characteristics
comparable to national registry. Therefore, our data may be
representative of general thyroid cancer patients rendering it to
compensate for some of the possible bias. Secondly, patients with
pseudohyponatremia, dilutional hyponatremia, and polydipsia-
induced hyponatremia could not be excluded because serum and
urine osmolarity tests were not performed in all of the patients.
But, as shown in table 2, in severe hyponatremic patients with
available serum and urine osmolarity data, all of the patients
showed low serum osmolarity levels. Also, all patients who
underwent RAI therapy were clinically stable including well
controlled diabetes. Therefore, the possibility of pseudohypona-
tremia or dilutional hyponatremia could be excluded to some
extent. Lastly, as adrenal hormone or volume status in each
patient was unavailable, we could not confirm the isolated effect of
hypothyroidism in our patients. However, in cases of severe
patients admitted to the emergency room, the adrenal hormone
values were checked and had none showed severe abnormalities.
To the best of our knowledge, this is the first study to
systematically quantify the risk factors for the occurrence of
hyponatremia following RAI therapy; and thus this study differs
from previous case reports [4–10] with only limited number of
severe hyponatremic cases.
In conclusion, our data suggest that old age, female sex, thiazide
medication use, and hyponatremia at the start of RAI are risk
factors for developing hyponatremia following RAI therapy after
total thyroidectomy. Based on our study results, we recommend
that physicians should monitor the occurrence of hyponatremia
after RAI therapy in high-risk thyroid carcinoma patients who
have undergone total thyroidectomy, and should monitor electro-
lyte levels closely while the patients should stop taking thiazide
diuretics. Excessive hydration can further aggravate hyponatremia
in old age patients with electrolyte imbalance. Thus, we
recommend the use of isotonic or hypertonic saline instead of
sodium-free water drinking or intravenous infusion of hypotonic
fluid in order to prevent worsening of hyponatremia. Further,
prospective, interventional studies are warranted to evaluate the
benefits of discontinuing thiazide prior to RAI therapy in
preventing hyponatremia and in improving the clinical outcome,
particularly in elderly females.
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